Pre-made Foralumab benchmark antibody ( Whole mAb, anti-CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Foralumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Foralumab is a fully human monoclonal antibody that binds to CD3 epsilon. Also called TZLS-401, it is currently in clinical development by Tiziana Life Sciences for treatment of Crohn's disease and other autoimmune diseases.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-220-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Foralumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody
INN Name	Foralumab
Target	CD3E
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	Medarex;NovImmune SA;Harvard Medical School;Tiziana Life Sciences
Conditions Approved	na
Conditions Active	Crohn's disease;Neurodegenerative disorders;Primary biliary cirrhosis;Inflammatory bowel diseases;Non-alcoholic steatohepatitis;Type 2 diabetes mellitus
Conditions Discontinued	Transplant rejection;Type 1 diabetes mellitus
Development Tech	na